William Blair analyst Matt Phipps has reiterated their neutral stance on KROS stock, giving a Hold rating today.
Matt Phipps’s rating is based on the recent Phase I study results of KER-065, which showed promising biomarker trends but also raised some concerns. The study indicated potential improvements in body composition and a generally tolerable safety profile. However, the observation of hemoglobin elevations and a lack of dose response on some exploratory endpoints have left questions about the appropriate dosing and safety of KER-065.
Despite these promising signals, the uncertainties surrounding the dosing and safety liabilities, along with the early stage of the program, contribute to the Hold rating. Additionally, Keros’s future prospects are contingent upon the outcomes of regulatory discussions and the results from the discontinued TROPOS study of cibotercept in pulmonary arterial hypertension. These factors together suggest a cautious approach, as the company navigates its development path forward.
In another report released today, Wedbush also maintained a Hold rating on the stock with a $15.00 price target.